For research use only. Not for therapeutic Use.
Agomelatine (BAN, rINN; trade names Valdoxan, Melitor, Thymanax) is a melatonergic antidepressant developed by the pharmaceutical company Servier. It is marketed for the treatment of major depressive disorder and has been reported to not produce discontinuation syndrome and have no sexual side effects compared to SSRIs, SNRIs and the older tricyclic antidepressants. Agomelatine may also have positive effects on sleep. Agomelatine is a melatonergic agonist (MT1 and MT2 receptors) and 5-HT2C antagonist. Binding studies indicate that it has no effect on monoamine uptake and no affinity for α, β adrenergic, histaminergic, cholinergic, dopaminergic and benzodiazepine receptors.
| Catalog Number | A001136 |
| CAS Number | 138112-76-2 |
| Synonyms | 20098 |
| Molecular Formula | C15H17NO2 |
| Purity | ≥95% |
| Target | Neuronal Signaling |
| Solubility | Soluble in DMSO > 10 mM |
| Storage | 3 years -20C powder |
| InChI | InChI=1S/C15H17NO2/c1-11(17)16-9-8-13-5-3-4-12-6-7-14(18-2)10-15(12)13/h3-7,10H,8-9H2,1-2H3,(H,16,17) |
| InChIKey | YJYPHIXNFHFHND-UHFFFAOYSA-N |
| SMILES | COc1ccc2cccc(CCNC(=O)C)c2c1 |
| Reference | </br>1:Agomelatine in the treatment of mild-to-moderate depression in patients with cardiovascular disease: results of the national multicenter observational study PULSE. Medvedev VE.Neuropsychiatr Dis Treat. 2017 Apr 21;13:1141-1151. doi: 10.2147/NDT.S129793. eCollection 2017. PMID: 28461750 Free PMC Article</br>2:Agomelatine protects against neuronal damage without preventing epileptogenesis in the kainate model of temporal lobe epilepsy. Tchekalarova J, Atanasova D, Nenchovska Z, Atanasova M, Kortenska L, Gesheva R, Lazarov N.Neurobiol Dis. 2017 Apr 21;104:1-14. doi: 10.1016/j.nbd.2017.04.017. [Epub ahead of print] PMID: 28438504 </br>3:Bioequivalence and Pharmacokinetic Profiles of Agomelatine 25-mg Tablets in Healthy Chinese Subjects: A Four-Way Replicate Crossover Study Demonstrating High Intra- and Inter-individual Variations. Li C, Xu J, Zheng Y, Chen G, Wang J, Ma L, Qiao Y, Niu J, Wu M, Zhang H, Li X, Chen H, Zhu X, Liu C, Ding Y.Chem Pharm Bull (Tokyo). 2017 Apr 8. doi: 10.1248/cpb.c16-00866. [Epub ahead of print] PMID: 28392509 Free Article</br>4:Antidepressant effect in older depressed patients: the lessons of two agomelatine trials. Goodwin GM, Thomas P, Heun R, Boyer P, Picarel-Blanchot F, de Bodinat C.Int Clin Psychopharmacol. 2017 Apr 5. doi: 10.1097/YIC.0000000000000174. [Epub ahead of print] PMID: 28383308 </br>5:Effect of agomelatine on memory deficits and hippocampal gene expression induced by chronic social defeat stress in mice. Martin V, Allaïli N, Euvrard M, Marday T, Riffaud A, Franc B, Mocaër E, Gabriel C, Fossati P, Lehericy S, Lanfumey L.Sci Rep. 2017 Apr 4;8:45907. doi: 10.1038/srep45907. PMID: 28374847 Free PMC Article</br>6:Genome-wide analysis of LPS-induced inflammatory response in the rat ventral hippocampus: Modulatory activity of the antidepressant agomelatine. Rossetti AC, Paladini MS, Racagni G, Riva MA, Cattaneo A, Molteni R.World J Biol Psychiatry. 2017 Mar 24:1-12. doi: 10.1080/15622975.2017.1298839. [Epub ahead of print] PMID: 28337940 </br>7:Efficacy and safety of agomelatine (10 or 25 mg/day) in non-depressed out-patients with generalized anxiety disorder: A 12-week, double-blind, placebo-controlled study. Stein DJ, Ahokas A, Jarema M, Avedisova AS, Vavrusova L, Chaban O, Gruget C, Olivier V, Picarel-Blanchot F, de Bodinat C.Eur Neuropsychopharmacol. 2017 May;27(5):526-537. doi: 10.1016/j.euroneuro.2017.02.007. Epub 2017 Mar 12. PMID: 28298261 Free Article</br>8:The impact of antidepressant treatments on family functioning in adults with major depressive disorder: a post hoc comparison of vortioxetine and agomelatine. François C, Nielsen R, Danchenko N, Williams V, Lançon C.Curr Med Res Opin. 2017 Mar 28:1-10. doi: 10.1080/03007995.2017.1299701. [Epub ahead of print] PMID: 28277865 </br>9:Comparison between Two Linear Supervised Learning Machines/’ Methods with Principle Component Based Methods for the Spectrofluorimetric Determination of Agomelatine and Its Degradants. Elkhoudary MM, Naguib IA, Abdel Salam RA, Hadad GM.J Fluoresc. 2017 May;27(3):1149-1160. doi: 10.1007/s10895-017-2050-1. Epub 2017 Mar 1. PMID: 28251418 </br>10:Pooled Analysis of Four Non-Interventional Studies: Effectiveness and Tolerability of the Antidepressant Agomelatine in Daily Practice. Laux G, Barthel B, Hajak G, Lemke M, Volz HP.Adv Ther. 2017 Apr;34(4):895-914. doi: 10.1007/s12325-017-0485-z. Epub 2017 Feb 18. PMID: 28214983 |
